Cargando…
Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage
The ribosome inactivating proteins (RIPs) efficiently decrease the microbial infections in plants. Momordica charantia MAP30 is a type I RIP that has not been investigated against plant viruses or bacteriophages. To evaluate of these activities, the recombinant MAP30 (rMAP30) was produced in the hai...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902390/ https://www.ncbi.nlm.nih.gov/pubmed/36747030 http://dx.doi.org/10.1038/s41598-023-29365-7 |
_version_ | 1784883250658803712 |
---|---|
author | Amirzadeh, Nafiseh Moghadam, Ali Niazi, Ali Afsharifar, Alireza |
author_facet | Amirzadeh, Nafiseh Moghadam, Ali Niazi, Ali Afsharifar, Alireza |
author_sort | Amirzadeh, Nafiseh |
collection | PubMed |
description | The ribosome inactivating proteins (RIPs) efficiently decrease the microbial infections in plants. Momordica charantia MAP30 is a type I RIP that has not been investigated against plant viruses or bacteriophages. To evaluate of these activities, the recombinant MAP30 (rMAP30) was produced in the hairy roots of Nicotiana tabacum. Inoculation of 3 μg of transgenic total protein or 0.6 μg of rMAP30 against 0.1 μg of TMV reduced the leaf necrotic spots to 78.23% and 82.72%, respectively. The treatment of 0.1 μg of CMV with rMAP30 (0.6 μg) showed the reduction in the leaf necrotic spots to 85.8%. While the infection was increased after rMAP30 dilution. In the time interval assays, the leaves were first inoculated with 1 μg of rMAP30 or 0.1 μg of purified TMV or CMV agent for 6 h, then virus or protein was applied in order. This led the spot reduction to 35.22% and 67% for TMV, and 38.61% and 55.31% for CMV, respectively. In both the pre- and co-treatments of 1:10 or 1:20 diluted bacteriophage with 15 μg of transgenic total protein, the number and diameter of the plaques were reduced. The results showed that the highest inhibitory effect was observed in the pre-treatment assay of bacteriophage with transgenic total protein for 24 h. The decrease in the growth of bacteriophage caused more growth pattern of Escherichia coli. The results confirm that rMAP30 shows antibacterial activity against Streptococcus aureus and E. coli, antifungal activity against Candida albicans, and antiviral activity against CMV and TMV. Moreover, rMAP30 exhibits anti-phage activity for the first time. According to our findings, rMAP30 might be a valuable preservative agent in foods and beverages in the food industry as well as an antiviral and antimicrobial mixture in agriculture. |
format | Online Article Text |
id | pubmed-9902390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99023902023-02-08 Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage Amirzadeh, Nafiseh Moghadam, Ali Niazi, Ali Afsharifar, Alireza Sci Rep Article The ribosome inactivating proteins (RIPs) efficiently decrease the microbial infections in plants. Momordica charantia MAP30 is a type I RIP that has not been investigated against plant viruses or bacteriophages. To evaluate of these activities, the recombinant MAP30 (rMAP30) was produced in the hairy roots of Nicotiana tabacum. Inoculation of 3 μg of transgenic total protein or 0.6 μg of rMAP30 against 0.1 μg of TMV reduced the leaf necrotic spots to 78.23% and 82.72%, respectively. The treatment of 0.1 μg of CMV with rMAP30 (0.6 μg) showed the reduction in the leaf necrotic spots to 85.8%. While the infection was increased after rMAP30 dilution. In the time interval assays, the leaves were first inoculated with 1 μg of rMAP30 or 0.1 μg of purified TMV or CMV agent for 6 h, then virus or protein was applied in order. This led the spot reduction to 35.22% and 67% for TMV, and 38.61% and 55.31% for CMV, respectively. In both the pre- and co-treatments of 1:10 or 1:20 diluted bacteriophage with 15 μg of transgenic total protein, the number and diameter of the plaques were reduced. The results showed that the highest inhibitory effect was observed in the pre-treatment assay of bacteriophage with transgenic total protein for 24 h. The decrease in the growth of bacteriophage caused more growth pattern of Escherichia coli. The results confirm that rMAP30 shows antibacterial activity against Streptococcus aureus and E. coli, antifungal activity against Candida albicans, and antiviral activity against CMV and TMV. Moreover, rMAP30 exhibits anti-phage activity for the first time. According to our findings, rMAP30 might be a valuable preservative agent in foods and beverages in the food industry as well as an antiviral and antimicrobial mixture in agriculture. Nature Publishing Group UK 2023-02-06 /pmc/articles/PMC9902390/ /pubmed/36747030 http://dx.doi.org/10.1038/s41598-023-29365-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Amirzadeh, Nafiseh Moghadam, Ali Niazi, Ali Afsharifar, Alireza Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title | Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title_full | Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title_fullStr | Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title_full_unstemmed | Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title_short | Recombinant anti-HIV MAP30, a ribosome inactivating protein: against plant virus and bacteriophage |
title_sort | recombinant anti-hiv map30, a ribosome inactivating protein: against plant virus and bacteriophage |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902390/ https://www.ncbi.nlm.nih.gov/pubmed/36747030 http://dx.doi.org/10.1038/s41598-023-29365-7 |
work_keys_str_mv | AT amirzadehnafiseh recombinantantihivmap30aribosomeinactivatingproteinagainstplantvirusandbacteriophage AT moghadamali recombinantantihivmap30aribosomeinactivatingproteinagainstplantvirusandbacteriophage AT niaziali recombinantantihivmap30aribosomeinactivatingproteinagainstplantvirusandbacteriophage AT afsharifaralireza recombinantantihivmap30aribosomeinactivatingproteinagainstplantvirusandbacteriophage |